On June 30, 2023, Shanghai AEFS Pharmaceutical Technology Co., LTD. 's single-dose eye drops production project groundbreaking ceremony was successfully held in Xinzhuang Industrial Zone, Minhang, Shanghai. The industrial land area of the project is 41 mu, and 706 million yuan will be invested in the construction of a single-dose sterile eye drops industry project, which is committed to building a green intelligent biomedical manufacturing base. After the completion of the project, 307.5 million single-dose sterile eye drops can be produced per year.
The project is located in Minhang District of Shanghai, and Minhang's open and innovative business environment is a new opportunity for Eyefirst. Lin Tianyi, chairman of Shanghai Eyefirst Pharmaceutical Technology Co., LTD., said that the "three-year plan" promotes the construction of industrial innovation carriers, and the construction of manufacturing innovation centers, technological innovation centers and industrial innovation centers. The Group company has a key enterprise research institute, equipped with advanced experimental instruments and testing equipment, with CNAS testing center and other qualifications, the company is currently researching 7 eye drop products. The company is constantly expanding the technology research and development team, improving the scientific research strength, expanding new directions, and promoting the transformation and upgrading of the manufacturing industry from "manufacturing" to "intelligent manufacturing", promoting innovation and creation.
AEFS is positioned in the golden track of ophthalmic medicine, and will continue to focus on the development of human eye health. After the completion of the project, Eyefirst will produce eye drops for controlling myopia of teenagers and children, antibacterial, anti-inflammatory and anti-infection eye drops, and eye drops for treating dry eye diseases
Adhering to the concept of innovation, the company realizes the independent research and development and production of new drugs, constantly develops safer high-quality high-end cutting-edge ophthalmic products, and strives to become a first-class enterprise in the field of ophthalmology with independent core technology and intellectual property rights, and contributes to the development of China's eye health cause!